Quest Diagnostics lifts FY outlook after broad-based growth powers Q2 beat
DGX•Updated 2026 guidance
- 2026 revenue outlook: $11.95 billion-$12.05 billion, up from $11.78 billion-$11.90 billion
- 2026 reported diluted EPS forecast: $9.97-$10.17, up from $9.58-$9.78
- 2026 adjusted diluted EPS forecast: $11.05-$11.25, up from $10.63-$10.83
What drove the quarter
Nearly all revenue growth came from organic gains across physician, hospital, and consumer channels.
Double-digit revenue growth in Advanced Diagnostics, including Alzheimer's and cardiometabolic tests, contributed to results.
Robust revenue growth from questhealth.com and consumer, wearable, and wellness partners also supported the quarter.
Key quarterly figures and analyst view
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $3.04 billion | $2.97 billion (14 analysts) |
| Q2 Adjusted EPS | Beat | $3.12 |
